← Back

Wire · opportunities

Roche and Eli Lilly Win FDA Clearance for Alzheimer's Blood Test

Published

25 August 2026

Topic

opportunities

Sectors

Diagnostics

Geography

United States

Source

Read at finance.yahoo.com

Verified

Fusion42 · 25 August 2026 · Fusion42 review

Roche and Eli Lilly received FDA clearance for Elecsys pTau217, a blood test detecting Alzheimer's-related brain changes in people 55 and older with cognitive decline. The test leverages Roche's extensive US lab analyser network and will be offered via Labcorp and Quest Diagnostics, simplifying and broadening access to Alzheimer's diagnostics.

This Wire brief sits within Fusion42's coverage of Diagnostics, and 3 sources have reported it between 24 Aug 2026 and 25 Aug 2026.

◆ The Wire takeaway

You can now enter the US Alzheimer's diagnostics market with a blood test that avoids costly scans and invasive procedures. Labcorp and Quest Diagnostics backing means rapid scaling opportunities for your offering in routine clinical care.

Coverage

3 sources · first reported 24 Aug 2026 · latest 25 Aug 2026

Related on Wire

Topics

DiagnosticsalzheimersdiagnosticsFDA-clearanceblood-testRocheEli-Lilly